A Phase 1b Study of Imvotamab in Moderate to Severe Rheumatoid Arthritis

Stopped early · Phase 1 · Has a placebo group

Conditions studied: Rheumatoid Arthritis, Arthritis, Rheumatoid, Arthritis

In brief

The purpose of this study is to determine the safety and tolerability of imvotamab in patients with moderate to severe rheumatoid arthritis who have failed prior therapies. Participants will be given imvotamab or placebo through a vein (i.e., intravenously). A placebo is a look-alike substance that contains no active drug

Key facts

Study ID
NCT06087406
Run by
IGM Biosciences, Inc.
People needed
33
Starts
2023-03-15
Expected to finish
2025-02-10
Last updated by the study team
2025-02-18

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.